Osage University Partners — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
PMV Pharmapmvpharma.comFeb 2017
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)Steve Winick(Director)Arnold Oronsky(Director)
Co-investorsAvoro Capital AdvisorsNextech InvestOUP (Osage University Partners)RA CapitalOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.